iDPP@CLEF 2022

Intelligent Disease Progression Prediction at CLEF



Motivation: What is ALS?

Amyotrophic Lateral Sclerosis (ALS) is a chronic disease, characterized by progressive or alternate impairment of neurological functions (motor, sensory, visual, cognitive). Patients have to manage alternated periods in hospital with care at home, experiencing a constant uncertainty regarding the timing of the disease acute phases and facing a considerable psychological and economic burden that also involves their caregivers. Clinicians, on the other hand, need tools able to support them in all the phases of the patient treatment, suggest personalized therapeutic decisions, indicate urgently needed interventions.

Goal

The goal of iDPP@CLEF is to design and develop an evaluation infrastructure for AI algorithms able to:



better describe disease mechanisms;



stratify patients according to their phenotype assessed all over the disease evolution;



predict disease progression in a probabilistic, time dependent fashion.

iDPP@CLEF 2022 organizes the following activities:

it focuses on ranking of patients based on the risk of impairment, e.g. NIV, PEG, or death. More in detail, we use the ALSFRS-R scale to monitor speech, swallowing, handwriting, dressing/ hygiene, walking and respiratory ability in time and will ask participants to rank patients based on time to event risk of experiencing impairment in each specific domain.

it refines Task 1 asking participants to predict when specific impairments will occur (i.e. in the correct time-window). In this regard, we assess model calibration in terms of the ability of the proposed algorithms to estimate a probability of an event close to the true probability within a specified time-window.

We evaluate proposals of different visualization frameworks able to show the multivariate nature of the data and the model predictions in an explainable, possibly interactive, way.

Datasets

The iDPP@CLEF 2022 challenge will share three valuable datasets for both training and testing algorithms to predict the progression of ALS and/or to showcase approaches for the explainability of such algorithms. These datasets come from two clinical institutions, one in Lisbon (Portugal), and the other in Turin (Italy) and contain data about real patients, fully anonymized.

Dataset A: is intended for the prediction of NIV - Non-invasive ventilation (or the competing event Death) and consists of 1,804 patients and 6,002 visits (ALSFRS-R questionnaires, Spirometry, etc.).

Dataset B: is intended for the prediction of PEG – Percutaneous Endoscopic Gastrostomy (or the competing event Death) and consists of 2,145 patients and 7,180 visits (ALSFRS-R questionnaires, Spirometry, etc.).

Dataset C: is intended for the prediction of Death and consists of 2,250 patients and 7,536 visits (ALSFRS-R questionnaires, Spirometry, etc.).

All the datasets are split into a training and test set according to a (approximately) 80%-20% ratio.

Important Dates

Registration closes: April 22, 2022 Runs submission deadline: May 6, 2022 Evaluation results out: May 20, 2022

Participant & position paper submission deadline: May 27, 2022 Notification of acceptance for participant and position papers:

June 13, 2022

Camera-ready participant papers submission: July 1, 2022 iDPP@CLEF 2022 Workshop: September 5-8, 2022 during the **CLEF Conference**

Organizers

Adriano Chiò, University of Turin, Italy Arianna Dagliati, University of Pavia, Italy Barbara Di Camillo, University of Padua, Italy Mamede Alves de Carvalho, University of Lisbon, Portugal Nicola Ferro, University of Padua, Italy Piero Fariselli, University of Turin, Italy Sara C. Madeira, University of Lisbon, Portugal

More Information

Website: www.brainteaser.health/open-evaluation-challenges/idpp-2022/ Registration: www.clef2022-labs-registration.dei.unipd.it/ Participation guidelines: www.brainteaser.dei.unipd.it/challenges/idpp2022/



LifeSTech_























